Loading...
ROCO
4128
Market cap496mUSD
Jun 12, Last price  
27.70TWD
1D
9.80%
1Q
-17.92%
Jan 2017
56.62%
IPO
324.24%
Name

Microbio Co Ltd

Chart & Performance

D1W1MN
ROCO:4128 chart
P/E
—
P/S
9.46
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.71%
Rev. gr., 5y
3.28%
Revenues
1.72b
+8.26%
231,532,000155,603,000512,593,000737,671,0001,079,118,0001,194,787,0001,177,656,0001,167,834,0001,399,356,0001,518,853,0001,522,436,0001,412,791,0001,448,533,0001,466,308,0001,601,399,0001,782,038,0001,721,848,0001,591,392,0001,722,852,000
Net income
-1.10b
L-6.70%
-24,087,000-123,426,00025,940,000-81,767,000412,532,000280,368,000-33,290,000-129,116,000-140,426,000-193,692,000-267,815,000543,030,000-690,743,000-264,596,000519,839,000-233,160,000152,424,000-1,179,876,000-1,100,803,000
CFO
530m
P
4,388,000-95,298,000-143,212,000-485,097,000520,412,000-271,949,000-132,360,000-176,632,000-167,037,000-161,895,000-180,247,000-9,830,00015,849,00072,359,000109,817,00053,981,000141,566,000-118,754,000529,901,000
Dividend
Jun 16, 20230.0401 TWD/sh

Profile

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.
URL
https://www.microbio.com.tw/
IPO date
Feb 10, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,722,852
8.26%
1,591,392
-7.58%
1,721,848
-3.38%
Cost of revenue
2,174,267
2,097,865
2,001,519
Unusual Expense (Income)
NOPBT
(451,415)
(506,473)
(279,671)
NOPBT Margin
Operating Taxes
171
(553)
(598)
Tax Rate
NOPAT
(451,586)
(505,920)
(279,073)
Net income
(1,100,803)
-6.70%
(1,179,876)
-874.07%
152,424
-165.37%
Dividends
(20,444)
(18,653)
Dividend yield
0.08%
0.06%
Proceeds from repurchase of equity
93,436
BB yield
-0.32%
Debt
Debt current
149,065
142,544
119,473
Long-term debt
1,084,282
1,097,958
858,624
Deferred revenue
986,825
194,963
198,612
Other long-term liabilities
62,737
64,274
65,106
Net debt
(7,931,880)
(10,878,992)
(8,521,150)
Cash flow
Cash from operating activities
529,901
(118,754)
141,566
CAPEX
(22,579)
(48,042)
(43,120)
Cash from investing activities
(302,046)
(210,999)
334,558
Cash from financing activities
(166,860)
(163,079)
(67,119)
FCF
(591,118)
(555,041)
(185,432)
Balance
Cash
2,572,299
3,660,231
4,101,926
Long term investments
6,592,928
8,459,263
5,397,321
Excess cash
9,079,084
12,039,924
9,413,155
Stockholders' equity
6,370,007
10,264,465
8,272,791
Invested Capital
7,166,230
4,114,328
6,489,565
ROIC
ROCE
EV
Common stock shares outstanding
592,721
560,162
559,887
Price
33.00
-31.39%
48.10
-7.98%
52.27
-1.64%
Market cap
19,559,790
-27.41%
26,943,792
-7.93%
29,265,303
0.87%
EV
13,191,426
17,754,251
22,659,607
EBITDA
(184,833)
(261,305)
(37,189)
EV/EBITDA
Interest
10,133
7,382
6,097
Interest/NOPBT